Podium to Practice: Chicago 2026 – BREAST: NEO Healer – Anbenitamab + nab-Docetaxel ± Carboplatin vs THP ± Carboplatin in Neoadjuvant HER2+ Breast Cancer

Podium to Practice: Chicago 2026 – BREAST: NEO Healer – Anbenitamab + nab-Docetaxel ± Carboplatin vs THP ± Carboplatin in Neoadjuvant HER2+ Breast Cancer

Podium to Practice: Chicago 2026

Studies / Trials Discussed

LBA660 – Anbenitamab plus albumin-bound docetaxel (nab-docetaxel) ± carboplatin (Cb) versus trastuzumab and pertuzumab plus docetaxel (THP) ± Cb as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: A randomized, open-label, multicenter, phase 3 trial.

Icon Chair Speaker

Chair

Dr. Christine Simmons

Icon Chair Speaker

Speakers

Dr. Christine Brezden-Masley

Dr. Heather McArthur

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

LBA660 – Anbenitamab plus albumin-bound docetaxel (nab-docetaxel) ± carboplatin (Cb) versus trastuzumab and pertuzumab plus docetaxel (THP) ± Cb as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: A randomized, open-label, multicenter, phase 3 trial.
Tagged